Economic Crisis Expected To Shape UK’s Future Drug Pricing Deal
The pharmaceutical industry has warned the UK’s new government about the impact of unprecedented industry payments on medicines supply in the short term and their potential to reduce inward investment in the long term. Along with economic pressures, these considerations will be among the factors forming the backdrop to negotiations on a deal that will determine pricing and access for branded medicines from 2024 onwards.
You may also be interested in...
The UK government has confirmed plans to raise payments made by drug companies in the statutory scheme for branded medicines to 24.4% for 2023, despite clear warnings from industry that the approach is unsustainable and jeopardizes the delivery of the government's ambitions for life sciences in the post-Brexit UK.
Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.
An alliance of blood cancer charities has called for multi-indication and combination pricing to be introduced in the UK as part of a future pricing and access deal. The group also requested a transparent and formal way of involving patients as the government and industry negotiate a successor to the Voluntary Scheme for Branded Medicines Pricing and Access, which is due to end in 2023.